Antidote to Parkinson's
doi:10.1038/nindia.2010.54 Published online 28 April 2010
A few novel organic compounds might help alleviate the symptoms of Parkinson's disease.
In Parkinson's, neurons that make a chemical called dopamine die or do not work properly. Dopamine normally sends signals that help coordinate movements. Depletion of dopamine levels leads to movement disorders — slowing of physical movement (bradykinesia) and a loss of physical movement (akinesia) in extreme cases.
Given the harmful effects of drugs that target dopamine-secreting nerve cells, researchers have turned their attention to a new target called adenosine A2A receptors (cell surface proteins) in a specific region of brain.
These nerve cells interact with dopamine-secreting nerve cells and play a role in the pathogenesis of Parkinson's disease. To exploit the therapeutic option of the adenosine receptors, the researchers synthesised a novel class of organic compounds called thiazolotriazolopyrimidine derivatives.
In lab studies, they discovered that the compounds have high affinity with human adenosine receptors expressed in HEK (human embryonic kidney) 293 cells. In mice pre-treated with the novel compounds, attenuation of haloperidol-induced motor impairments (catalepsy and akinesia) was observed.